Zobrazeno 1 - 10
of 23
pro vyhledávání: '"AK Mylin"'
Autor:
Hans Gregersen, Bo Amdi Jensen, Christen Lykkegaard Andersen, Carsten Helleberg, Mikael Frederiksen, Morten Saaby Steffensen, AK Mylin, Niels Abildgaard, Bettina Broch, Mary Jarden, Henrik Frederiksen, Anja Klostergaard, Per Troellund Pedersen, Lene Kongsgaard Nielsen
Publikováno v:
HemaSphere. 2:1-1113
Autor:
AK Mylin, Lene Meldgaard Knudsen, Peter Gimsing, Hans Erik Johnsen, Torben Plesner, Niels Frost Andersen, Niels Abildgaard, Torben Mourits-Andersen, Henrik Gregersen, Annette Juul Vangsted
Publikováno v:
Hematology Reviews
Hematology Reviews; Volume 1; Issue 2; Pages: e11
Hematology Reports, Vol 1, Iss 2, Pp e11-e11 (2009)
Aalborg University
Johnsen, H E, Knudsen, L M, Mylin, A K, Gimsing, P, Gregersen, H, Abildgaard, N, Andersen, N F, Plesner, T, Vangsted, A J & Mouritz-Andersen, T 2009, ' Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial ', Hematology Reviews, vol. 1, no. 2, pp. 62-64 .
Hematology Reviews; Volume 1; Issue 2; Pages: e11
Hematology Reports, Vol 1, Iss 2, Pp e11-e11 (2009)
Aalborg University
Johnsen, H E, Knudsen, L M, Mylin, A K, Gimsing, P, Gregersen, H, Abildgaard, N, Andersen, N F, Plesner, T, Vangsted, A J & Mouritz-Andersen, T 2009, ' Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial ', Hematology Reviews, vol. 1, no. 2, pp. 62-64 .
Udgivelsesdato: 2009 The impact of chemotherapy resistant B cells in multiple myeloma (MM) needs to be evaluated by in vivo targeted therapy. Here we report the conclusions from a phase II randomized, placebo controlled trial adding fludarabine to th
Autor:
Lene Meldgaard Knudsen, Thomas Rasmussen, AK Mylin, Hans Erik Johnsen, Stig Lenhoff, Jens Hammerstrøm, O Roer
Publikováno v:
Cytotherapy. 8(1)
Pre-transplant clinical evaluation of autografting is an important step in predicting post-transplant support, complications and safety. Today, unfavorable outcomes such as early death or graft failure are rare, making them unsuitable for quality ass
Autor:
Nielsen LK; Department of Haematology, Quality of Life Research Center, Odense University Hospital, Odense, Denmark. lene.kongsgaard.nielsen@rsyd.dk.; Section of Haematology, Department of Internal Medicine, Gødstrup Hospital, Herning, Denmark. lene.kongsgaard.nielsen@rsyd.dk., Mercieca-Bebber R; University of Sydney, NHMRC Clinical Trials Centre, Sydney, NSW, Australia., Möller S; OPEN, Open Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Redder L; Department of Haematology, Quality of Life Research Center, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Jarden M; Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Andersen CL; Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Public Health, Research Unit for General Practice and Section of General Practice, University of Copenhagen, Copenhagen, Denmark., Frederiksen H; Department of Haematology, Quality of Life Research Center, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Svirskaite A; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark., Silkjær T; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark., Steffensen MS; Section of Haematology, Department of Internal Medicine, Gødstrup Hospital, Herning, Denmark., Pedersen PT; Department of Haematology, South West Jutland Hospital, Esbjerg, Denmark., Hinge M; Department of Haematology, Vejle Hospital, Vejle, Denmark., Frederiksen M; Department of Haematology, Hospital of Southern Jutland, Aabenraa, Denmark., Jensen BA; Department of Haematology, Zealand University Hospital, Roskilde, Denmark., Helleberg C; Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark., Mylin AK; Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark., Abildgaard N; Department of Haematology, Quality of Life Research Center, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., King MT; Department of Haematology, Quality of Life Research Center, Odense University Hospital, Odense, Denmark.; School of Psychology, University of Sydney, Sydney, Australia.
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2024 Sep; Vol. 33 (9), pp. 2387-2400. Date of Electronic Publication: 2024 Jun 16.
Autor:
Westin O; The Heart Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark. Electronic address: oscar.mikael.westin@regionh.dk., Fosbøl EL; The Heart Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark., Maurer MS; Columbia University Irving Medical Center, New York, New York, USA., Leicht BP; Gildhøj Private Hospital, Copenhagen, Denmark., Hasbak P; Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, Denmark., Mylin AK; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Rørvig S; Department of Pathology, Rigshospitalet, Copenhagen, Denmark., Lindkær TH; Department of Pathology, Rigshospitalet, Copenhagen, Denmark., Johannesen HH; Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, Denmark., Gustafsson F; The Heart Center, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
Publikováno v:
Journal of the American College of Cardiology [J Am Coll Cardiol] 2022 Sep 06; Vol. 80 (10), pp. 967-977.
Autor:
Sørensen J; Section of Palliative Medicine, Rigshospitalet, Copenhagen, Denmark., Sørensen TV; Section of Palliative Medicine, Rigshospitalet, Copenhagen, Denmark., Andersen KH; Department of Anesthesiology, Rigshospitalet, Copenhagen, Denmark., Nørøxe ADS; Department of Oncology, and Rigshospitalet, Copenhagen, Denmark., Mylin AK; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Publikováno v:
Palliative medicine reports [Palliat Med Rep] 2022 Jan 04; Vol. 3 (1), pp. 369-373. Date of Electronic Publication: 2022 Jan 04 (Print Publication: 2022).
Autor:
Nielsen LK; Department of Haematology, Quality of Life Research Center, Odense University Hospital, Odense, Denmark. lene.kongsgaard.nielsen@rsyd.dk.; OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark. lene.kongsgaard.nielsen@rsyd.dk., King M; Department of Haematology, Quality of Life Research Center, Odense University Hospital, Odense, Denmark.; Faculty of Science, School of Psychology, University of Sydney, Sydney, Australia., Möller S; OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Jarden M; Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark., Andersen CL; Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark., Frederiksen H; Department of Haematology, Quality of Life Research Center, Odense University Hospital, Odense, Denmark., Gregersen H; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark., Klostergaard A; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark., Steffensen MS; Department of Haematology, Regional Hospital West Jutland, Holstebro, Denmark., Pedersen PT; Department of Haematology, South West Jutland Hospital, Esbjerg, Denmark., Hinge M; Department of Internal Medicine, Vejle Hospital, Vejle, Denmark., Frederiksen M; Department of Haematology, Hospital of Southern Jutland, Aabenraa, Denmark., Jensen BA; Department of Haematology, Zealand University Hospital, Roskilde, Denmark., Helleberg C; Department of Haematology, Herlev Hospital, Herlev, Denmark., Mylin AK; Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark., Abildgaard N; Department of Haematology, Quality of Life Research Center, Odense University Hospital, Odense, Denmark.; The Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2020 Feb; Vol. 29 (2), pp. 335-346. Date of Electronic Publication: 2019 Sep 23.
Autor:
Westhrin M; 1Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; 2Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway., Moen SH; 1Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; 2Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway., Kristensen IB; 3Department of Hematology, Odense University Hospital, Odense, Denmark., Buene G; 1Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; 2Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway., Mylin AK; 4Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Turesson I; 5Department of Hematology, Skane University Hospital, Malmo, Sweden., Abildgaard N; 3Department of Hematology, Odense University Hospital, Odense, Denmark., Waage A; 1Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; 6Department of Hematology, St. Olav's University Hospital, Trondheim, Norway., Standal T; 1Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; 2Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway.; 6Department of Hematology, St. Olav's University Hospital, Trondheim, Norway.
Publikováno v:
Biomarker research [Biomark Res] 2018 Jun 14; Vol. 6, pp. 21. Date of Electronic Publication: 2018 Jun 14 (Print Publication: 2018).
Autor:
Westhrin M; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Moen SH; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Holien T; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Mylin AK; Department of Haematology, Rigshospitalet, University of Copenhagen, Denmark., Heickendorff L; Department of Clinical Biochemistry, Aarhus University Hospital, Denmark., Olsen OE; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Sundan A; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Turesson I; Department of Hematology, Skane University Hospital, Malmo, Sweden., Gimsing P; Department of Haematology, Rigshospitalet, University of Copenhagen, Denmark., Waage A; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Standal T; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway therese.standal@ntnu.no.
Publikováno v:
Haematologica [Haematologica] 2015 Dec; Vol. 100 (12), pp. e511-4. Date of Electronic Publication: 2015 Aug 20.
Autor:
Olsen OE; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Post box 8905, MTFS, N-7491, Trondheim, Norway. oddrun.e.olsen@ntnu.no., Wader KF; Departments of Oncology, and Hematology, St. Olav's University Hospital, Trondheim, Norway. Karin.Inger.Martina.Fahl.Wader@stolav.no., Hella H; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Post box 8905, MTFS, N-7491, Trondheim, Norway. hanne.hella@ntnu.no., Mylin AK; Department of Haematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. anne.k.mylin@dadlnet.dk., Turesson I; Department of Hematology and Coagulation Disorders, Skane University Hospital, Malmö, Sweden. ingemar.turesson@med.lu.se., Nesthus I; Department of Medicine, Haukeland University Hospital, Bergen, Norway. inesthus@broadpark.no., Waage A; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Post box 8905, MTFS, N-7491, Trondheim, Norway. anders.waage@ntnu.no.; Departments of Hematology, St. Olav's University Hospital, Trondheim, Norway. anders.waage@ntnu.no., Sundan A; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Post box 8905, MTFS, N-7491, Trondheim, Norway. anders.sundan@ntnu.no.; CEMIR (Centre of Molecular Inflammation Research), Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. anders.sundan@ntnu.no., Holien T; K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Post box 8905, MTFS, N-7491, Trondheim, Norway. toril.holien@ntnu.no.
Publikováno v:
Cell communication and signaling : CCS [Cell Commun Signal] 2015 Jun 06; Vol. 13, pp. 27. Date of Electronic Publication: 2015 Jun 06.